MedTrace Logo

Postoperative Analgesia in Laparoscopic Abdominal Surgery After Exparel Via TAP or Local Infiltration

NCT03927326 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2019-04-25

No results posted yet for this study

Summary

This study evaluates differences in how administering liposomal bupivacaine via two different methods affects postoperative pain control in laparoscopic abdominal surgery patients. Half the participants will receive liposomal bupivacaine via a transverses abdominis plane block while the other half will receive liposomal bupivacaine via local infiltration.

Conditions

  • Pain, Postoperative
  • Anesthesia, Local
  • Anesthesia; Functional
  • Anesthesia
  • Opioid Use

Interventions

DRUG

Exparel 266 MG Per 20 ML Injection

Liposomal bupivacaine

Sponsors & Collaborators

Principal Investigators

  • Vanessa Loland, MD · University of Washington

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-08-31
Primary Completion
2020-07-31
Completion
2020-07-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03927326 on ClinicalTrials.gov